<DOC>
	<DOCNO>NCT00003008</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness paclitaxel treat patient AIDS-related Kaposi 's sarcoma .</brief_summary>
	<brief_title>Paclitaxel Treating Patients With AIDS-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether body distribution plasma clearance paclitaxel affect protease inhibitor ( e.g. , indinavir , ritonavir , saquinavir mesylate , nelfinavir mesylate ) . OUTLINE : Patients stratify accord protease inhibitor treatment ( yes v ) , prior paclitaxel ( yes v ) , prior doxorubicin daunorubicin ( yes v ) . Patients receive paclitaxel IV 3 hour day 1 . Treatment continue every 2 week least 1 course absence disease progression unacceptable toxicity . Patients previously receive paclitaxel receive 1 course study . PROJECTED ACCRUAL : A total 33 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Kaposi 's sarcoma require chemotherapy and/or currently treat paclitaxel Serologic diagnosis HIV infection document positive ELISA confirm Western Blot federally approve HIV diagnostic test PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,000/mm ^3 ( without use colonystimulating factor ) Platelet count least 50,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST great 2.5 time ULN Alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Neurologic : No great grade 2 peripheral neuropathy No neuropsychiatric history alter mental status would preclude study Other : Not pregnant nursing Fertile patient must use effective contraception No prior concurrent malignancy except curatively treat carcinoma situ cervix basal cell squamous cell skin cancer No sensitivity E. coliderived proteins No active untreated infection No new infectious complication require change antibiotic within past 2 week PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : At least 1 week since prior radiotherapy No prior radiotherapy marker lesion No concurrent radiotherapy Surgery : Not specify Other : At least 2 week since prior systemic treatment Kaposi 's sarcoma At least 2 week since prior nonapproved FDA investigational agent except available Investigational New Drugs antiretroviral agent Concurrent maintenance therapy opportunistic infection allow Concurrent commercially available antiretroviral therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>AIDS-related Kaposi sarcoma</keyword>
	<keyword>recurrent Kaposi sarcoma</keyword>
</DOC>